Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Aspirin Use for Heart Disease Prevention May Benefit Those with Coronary Artery Calcium Deposits

By BiotechDaily International staff writers
Posted on 21 May 2014
Image: Figure A shows the location and angle of the coronary calcium scan image. Figure B is a coronary calcium scan image showing calcifications in a coronary artery (Photo courtesy of the [US] National Heart, Lung, and Blood Institute).
Image: Figure A shows the location and angle of the coronary calcium scan image. Figure B is a coronary calcium scan image showing calcifications in a coronary artery (Photo courtesy of the [US] National Heart, Lung, and Blood Institute).
A recent study found that taking aspirin to prevent heart disease benefits individuals with high coronary artery calcium (CAC) scores but can actually cause damage from bleeding in individuals with low levels of coronary artery calcium.

An individual's CAC score is determined by using computerized tomography (CT) to scan the coronary blood vessels. Calcium deposits show up as bright white spots on the scan.

Investigators at the Minneapolis Heart Institute (MN, USA) monitored 4,229 individuals participating in the Multi-Ethnic Study of Atherosclerosis (MESA) at six centers in the USA. Participants had no known CVD (cardiovascular disease) or diabetes, were not on aspirin therapy, and were followed for approximately seven years.

Results revealed that participants with elevated CAC scores (greater than 100) were two to four times more likely to benefit from aspirin therapy than to be harmed, even if they did not qualify for aspirin use according to current American Heart Association guidelines. Conversely, MESA participants with no calcified plaque (CAC score = zero) were two to four times more likely to be harmed by aspirin use than to benefit.

“We estimate that individuals with significant plaque buildup in the arteries of the heart are much more likely to prevent a heart attack with aspirin use than to suffer a significant bleed,” said first author Dr. Michael D. Miedema, a preventative cardiologist at the Minneapolis Heart Institute. “On the opposite end of the spectrum, if you do not have any calcified plaque, our estimations indicate that use of aspirin would result in more harm than good, even if you have risk factors for heart disease such as high cholesterol or a family history of the disease.”

“A CAC score of zero is associated with a very low risk of having a heart attack. That means individuals with a score of zero may not benefit from preventive medications, such as aspirin as well as the cholesterol-lowering statin medications. Approximately 50% of middle-aged men and women have a CAC score of zero, so there is a potential for this test to personalize the approach to prevention and allow a significant number of patients to avoid preventive medications, but we need further research to verify that routine use of this test is the best option for our patients.”

The study was published in the May 6, 2014, online edition of the journal Circulation: Cardiovascular Quality and Outcomes.

Related Links:

Minneapolis Heart Institute



Channels

Genomics/Proteomics

view channel
Image: Bacteriophage EFDG1 visualized by transmission electron microscopy (TEM) at a magnification of 20,000–30,000 times. Note that some phages are still bound to remains of the dead bacteria (Photo courtesy of the Hebrew University of Jerusalem).

Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis. E. faecalis, a bacterium inhabiting... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.